XBRANE BIOPHARMA AB
BiotechXBRANE BIOPHARMA AB is a biotechnology company focused on Ophthalmology.
XBRANE BIOPHARMA AB's Key Drugs
XBRANE BIOPHARMA AB's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
XBRANE BIOPHARMA AB's Recent FDA Approvals
XBRANE BIOPHARMA AB secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
XBRANE BIOPHARMA AB's Therapeutic Areas
XBRANE BIOPHARMA AB's approved drugs and pipeline span 1 therapeutic area, led by Ophthalmology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
XBRANE BIOPHARMA AB's Top Competitors
XBRANE BIOPHARMA AB's closest competitors by therapeutic-area and drug-target overlap include Novartis, Baxter, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
XBRANE BIOPHARMA AB Pipeline Snapshot
XBRANE BIOPHARMA AB has 1 active clinical program from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Ophthalmology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2026-10-27
- Latest
- 2026-10-27
- Applications
- 1